Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

Biotron (ASX: BIT) shares up 126% - Management says we’ve no clue, Mate

It is possible to work out why the share price is leaping here, hope

Update : 02 Oct 2023, 12:45 PM

Biotron (ASX: BIT) (OTCPK: BITRF) shares are up 126% in the last four days. BIT shares are also up 33% today. The exchange has asked management why this is - or do they know of any reason why this is. To which the answer is Nope, no clue. Or at least that’s one way of thinking about this and it’s not quite the right way. It’s actually pretty easy to work out why Biotron shares are rising - Hope. And what management is saying is that they don't know of any other reason than that, not that they know of no reason.

The business line at Biotron: “Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections.” So the idea under development is one of those cure-all ideas. Hugely, massively, valuable if it does in fact work. But of course there’s a low probability of something like that working. 

As to why the BIT share price rising, there’s this letter from management: “I am pleased to report that Biotron is in the final stage of three Phase 2 clinical trials for HIV‐1 and COVID‐19. This is a pivotal time for the Company as it completes data collection and analyses of samples and information collected during the trials ahead of release of headline data in coming weeks. Phase 2 trials provide key value inflection points. “ Phase II trial is, effectively, the test of whether it works or not. So, if that’s all coming to a close then we might grain the news of whether it does work or not. And this that hope value being built into hte Biotron share price.

Biotron share price from Google Finance

However, the exchange has asked management to explain, if they can, the share price rise. The answer? No idea. Except that’s not quite the question asked. Which is, instead, is there any reason you know of which is not already public information? To which the answer is not - there’s no inside information that is. The company does not know the result of the Phase II trials as yet- it just knows what it has already publically declared. This is, we all agree, a different thing? 

Of course management knows that the share price is rising on that hope of the upcoming results. But that’s public knowledge already.

Now, we are the most dreadful, dreadful, cynics. So we would actually expect the next action to be a fundraise at Biotron. But that’s just because we are such dreadful cynics.

Top Brokers